In Silico Trial (IST) technologies refer to modeling and simulation tools used for the development and regulatory assessment of medicines and medical devices. These tools can significantly decrease the need for animal and human testing and reduce the costs of developing medical products while maintaining reliability.
The lack of trained personnel is one of the main reasons the use of in silico trials technologies is not widespread. To address this issue, within the In Silico World project, we are developing dedicated course modules to train and retrain individuals with the technical skills needed to work with in silico trials technologies.
To ensure that the courses are effective, we first have to define and assign Intended Learning Outcomes (ILOs) to every different stakeholder category. ILO is the centrepiece of the definition of training or retraining curricula and defines what a learner will acquire and will be able to do upon successfully completing their studies.
Our KU Leuven partners (Klaas Vander Linden, Jos Vander Sloten) in collaboration with Alma Mater Studiorum – Università di Bologna (Giorgio Davico, Marco Viceconti) provided us with “A systematic approach to define intended learning outcomes for different stakeholders for In Silico Trials”.
Access the full document via Zenodo
